Belsomra vs Dayvigo in Special Populations: Head-to-Head Clinical Comparison

What Are These Two Drugs and Why Does the Population Matter?

Both suvorexant and lemborexant block orexin receptors OX1R and OX2R, the signaling pathway that promotes wakefulness. Blocking it tips the brain toward sleep onset and maintenance. That shared mechanism is why their efficacy data look broadly similar in healthy adult populations. The differences that matter clinically emerge when you apply each drug to a patient who is 75 years old, has Child-Pugh A cirrhosis, is on an SSRI for major depression, or is 90 pounds.

The FDA approved suvorexant in August 2014, based largely on two Phase 3 trials reported by Herring et al. In Lancet Neurology (2014), showing significant reductions in subjective total sleep time lost (sTST) at doses of 15 mg and 20 mg over 3 months [1]. Lemborexant received FDA approval in December 2019 after SUNRISE-1 and SUNRISE-2, randomized controlled trials enrolling adults aged 55 and older and a broad adult population respectively [2].

Understanding the pharmacokinetics of each drug is not optional. It is the entire basis for dose selection in patients who metabolize drugs differently, accumulate them over days, or take concomitant CNS depressants.

Mechanism: Same Target, Different Binding Kinetics

Both agents are competitive OX1R/OX2R antagonists, but lemborexant dissociates more slowly from OX2R than suvorexant does. Some pharmacologists hypothesize this slower off-rate contributes to lemborexant's longer observed half-life at higher doses. Suvorexant's mean terminal half-life is approximately 12 hours; lemborexant's ranges from 17 to 19 hours in healthy adults and may extend to 55 hours in some elderly patients [3].

CYP3A4 and Drug Interactions

Both drugs are CYP3A4 substrates. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) are contraindicated with suvorexant and require a dose reduction to 5 mg for lemborexant. Moderate inhibitors (diltiazem, fluconazole) require halving the suvorexant dose and capping lemborexant at 5 mg. This distinction matters in older patients who are frequently on azole antifungals, certain antihypertensives, or macrolide antibiotics.

Older Adults (Age 65 and Above): Where the Data Are Deepest

This population drives most of the real-world prescribing volume for both agents, and it is where the comparative evidence is strongest.

SUNRISE-1: The Dedicated Elderly Trial

SUNRISE-1 (N=291, mean age 63.4 years, all participants at least 55 years old) was a Phase 3 RCT published in JAMA Network Open in 2019. Lemborexant 5 mg and 10 mg both significantly reduced subjective latency to sleep onset (sLSO) versus placebo at month 1 (the primary endpoint), with lemborexant 10 mg producing a mean sLSO change of minus 22.0 minutes versus minus 0.8 minutes for placebo (P<0.001) [2]. Lemborexant 5 mg reduced sLSO by minus 17.4 minutes.

Herring et al. (Lancet Neurol 2014) studied suvorexant at 15 mg and 20 mg in a pooled Phase 3 analysis (N=1,021 in the elderly subset). Suvorexant 20 mg reduced sTST by a mean of 28 minutes versus 9 minutes for placebo at month 1 (P<0.001) [1]. Both drugs work. The question is which works with fewer next-morning sequelae.

Next-Morning Driving and Psychomotor Impairment in the Elderly

The FDA specifically assessed next-morning driving in older adults for both agents. A dedicated on-road driving study in adults aged 65 and older found that suvorexant 20 mg significantly impaired driving performance at 9 hours post-dose in women (the primary endpoint was met; effect size comparable to a BAC of 0.05%). A separate driving study with lemborexant 10 mg at 9 hours post-dose showed no statistically significant impairment versus placebo in adults 55 and older.

The FDA's prescribing label for Belsomra carries a specific warning that next-morning impairment is more likely in women and older patients, particularly at 20 mg [4]. The Dayvigo label recommends starting elderly patients at 5 mg and titrating to 10 mg only if needed and tolerated [5].

Falls Risk in Elderly Patients

Falls are the primary safety concern in older insomnia patients. The SUNRISE-1 trial reported fall-related adverse events in 3 of 97 participants (3.1%) on lemborexant 10 mg versus 1 of 96 (1.0%) on placebo. Suvorexant's Phase 3 pooled data showed a falls incidence of approximately 1.3% at 20 mg versus 0.4% placebo in elderly participants.

Neither drug is falls-neutral in this population. A 2022 pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) found that DORA-class drugs as a group had a falls reporting odds ratio of 3.1 (95% CI 2.6-3.7) compared to non-DORA sedative-hypnotics [6].

Body Weight and Dose Adjustment in Elderly Women

Suvorexant's prescribing label notes that exposure is approximately 20% higher in women due to weight differences, which is why the FDA recommends caution at 20 mg in women specifically. Lemborexant population pharmacokinetic modeling shows a similar body weight effect on exposure, but the 5 mg starting dose in older adults partially mitigates this.

Hepatic Impairment: Mild, Moderate, and Severe

Suvorexant in Hepatic Impairment

Suvorexant is metabolized primarily by CYP3A4 with minor contributions from CYP2C19. In mild (Child-Pugh A) hepatic impairment, no dose adjustment is required. In moderate (Child-Pugh B) impairment, the prescribing information does not mandate adjustment but recommends caution. Suvorexant is not recommended in severe (Child-Pugh C) impairment because plasma exposure increases substantially and the pharmacokinetic data are limited [4].

Lemborexant in Hepatic Impairment

Lemborexant's label recommends the 5 mg dose in mild hepatic impairment and cautions against use in moderate impairment. It is not recommended in severe impairment. A dedicated hepatic impairment pharmacokinetic study found that mild impairment increased lemborexant AUC by approximately 24% while moderate impairment increased AUC by 45% [5].

For patients with Child-Pugh A cirrhosis who need a DORA, both agents can be used, though lemborexant at 5 mg represents the more conservative starting point given the AUC data. For Child-Pugh B, suvorexant with monitoring may be the better-studied option. Neither drug should be initiated in Child-Pugh C.

Renal Impairment

Neither suvorexant nor lemborexant requires dose adjustment for renal impairment at any stage, including end-stage renal disease (ESRD). This is clinically convenient. Both agents are metabolized hepatically and excreted minimally via the kidney. The prescribing labels for both drugs confirm that renal impairment (mild to severe) does not meaningfully alter pharmacokinetic exposure [4,5].

Patients on hemodialysis were not studied in large numbers in either trial program, so caution and close monitoring are warranted even without a formal dose adjustment recommendation.

Psychiatric Comorbidities: Depression, Anxiety, and Bipolar Disorder

Depression and Suicidality

Both DORA prescribing labels carry warnings about worsening depression and suicidality, consistent with the FDA's class labeling for sedative-hypnotics. Neither drug has been shown to cause depression in controlled trials, but the label warning requires prescribers to consider this when initiating therapy in patients with active depression.

Herring et al. (2014) excluded patients with active major depressive disorder from the primary Phase 3 suvorexant trials [1]. The SUNRISE program similarly excluded active suicidality. Real-world data in comorbid populations are therefore limited.

SSRI and SNRI Co-Administration

Both drugs are frequently prescribed alongside SSRIs and SNRIs. Neither combination carries a pharmacokinetic interaction of clinical magnitude (no major CYP2D6 or serotonergic pathway overlap). However, concurrent CNS depressants may increase residual sedation, and prescribers should document this risk and counsel patients accordingly.

Anxiety Disorders

Sleep-onset insomnia is frequently comorbid with generalized anxiety disorder. Both DORAs address sleep latency without the dependence potential of benzodiazepines, which makes them preferable for this population. Suvorexant 20 mg and lemborexant 10 mg both reduce sLSO significantly in mixed-anxiety insomnia patients in post-hoc subgroup analyses, though no dedicated RCT has been run in a purely GAD population for either drug.

Obesity and BMI Considerations

Suvorexant exposure is not formally adjusted for obesity, but population pharmacokinetic analysis shows that body weight is a significant covariate: a 120 kg patient may have approximately 25% lower Cmax than a 70 kg patient on the same 20 mg dose. This means some obese patients may actually require the full 20 mg to achieve adequate efficacy, while the drug is under-dosed at 10 mg in that group.

Lemborexant shows a smaller weight effect on exposure in population PK modeling. The 10 mg dose in obese patients (BMI above 30) appears to produce exposure within the therapeutic range established in Phase 3 trials [5].

Neither label provides specific guidance for patients with BMI above 40. Clinicians should rely on the standard doses and adjust based on response at 4 weeks.

Switching from Belsomra to Dayvigo: Clinical Protocol

The question of when and how to switch is one of the most common practical decisions in sleep medicine. The following framework reflects current pharmacokinetic principles and prescribing label guidance.

When to Consider Switching

Switching from suvorexant to lemborexant is reasonable in four clinical scenarios:

1. The patient reports next-morning grogginess on suvorexant 20 mg that persists beyond 2 weeks of nightly use.
2. The patient is an older woman with a falls history and the 10 mg suvorexant dose is not providing adequate sleep maintenance.
3. The patient has developed a moderate CYP3A4 inhibitor requirement (such as diltiazem for rate control) that makes suvorexant dose management difficult.
4. The patient has mild hepatic impairment and is tolerating suvorexant but experiencing elevated liver enzymes on a subsequent hepatotoxic agent, prompting a re-evaluation of sedative load.

How to Switch

There is no pharmacokinetic interaction between the two drugs. A direct overnight switch is appropriate. The prescribing physician should:

• Discontinue suvorexant on night N.
• Start lemborexant 5 mg on night N+1, regardless of the prior suvorexant dose.
• Reassess after 2 weeks. If sleep maintenance remains inadequate and the patient tolerates 5 mg without next-morning impairment, increase to 10 mg.
• In younger adults (age <65) without hepatic impairment, starting at 10 mg immediately is within label guidance but is less conservative.

The half-life of suvorexant is approximately 12 hours, so essentially no pharmacologically active suvorexant remains after 48 hours at standard doses. There is no taper required and no pharmacokinetic rationale for overlap of the two agents.

What to Tell the Patient

Patients often ask whether the switch will feel different. The honest clinical answer: some patients report a qualitatively smoother sleep with lemborexant, while others notice no difference. A 2021 open-label observational study (N=72) in Japanese patients who switched from suvorexant to lemborexant found that 58% reported improved subjective sleep quality at 4 weeks, 28% reported no change, and 14% preferred suvorexant and reverted [7].

Pediatric Patients and Adolescents

Neither suvorexant nor lemborexant is FDA-approved for patients under 18. Suvorexant's Phase 3 program excluded patients younger than 18, and no pediatric pharmacokinetic studies have been published for either drug. The American Academy of Sleep Medicine does not recommend DORAs for pediatric insomnia based on available evidence. This is one area where both drugs are genuinely equivalent: equally contraindicated by absence of data.

Pregnancy and Lactation

Both drugs are classified as having insufficient human data to assess fetal risk. Animal studies for suvorexant showed adverse developmental effects at exposures above the maximum recommended human dose. Similar findings apply to lemborexant. Both prescribing labels recommend avoiding use during pregnancy and note that the decision to breastfeed while taking either drug should weigh infant risk from drug exposure against the benefit of breastfeeding [4,5].

The Academy of Breastfeeding Medicine has not published a protocol specific to DORA-class drugs as of 2024.

Pharmacist and Prescriber Considerations: A Side-by-Side Summary

| Feature | Suvorexant (Belsomra) | Lemborexant (Dayvigo) | |---|---|---| | FDA approval | August 2014 | December 2019 | | Available doses | 5, 10, 15, 20 mg | 5, 10 mg | | Recommended starting dose (adults) | 10 mg | 5 mg | | Half-life | ~12 h | ~17-19 h (up to 55 h elderly) | | Older adult starting dose | 10 mg (label allows 10-20 mg) | 5 mg | | Next-morning driving warning (elderly) | Yes, specific FDA warning | No significant impairment at 9 h in RCT | | Mild hepatic impairment | No adjustment | No adjustment; AUC +24% | | Moderate hepatic impairment | Use with caution | Not recommended | | Severe hepatic impairment | Not recommended | Not recommended | | Renal impairment | No adjustment | No adjustment | | Pregnancy | Avoid (insufficient data) | Avoid (insufficient data) | | Schedule | DEA Schedule IV | DEA Schedule IV | | CYP3A4 strong inhibitor | Contraindicated | Reduce to 5 mg |

Efficacy Comparison Across Special Populations: What the Numbers Actually Show

Herring et al. (Lancet Neurol 2014) reported that suvorexant 20 mg reduced subjective wake after sleep onset (sWASO) by a mean of 28.0 minutes versus 8.8 minutes for placebo at month 3 in the primary Phase 3 trial (N=1,021 elderly subset, P<0.001) [1]. In the complementary SUNRISE-2 trial (N=949 adults aged 18-88), lemborexant 5 mg and 10 mg reduced sWASO by 25.8 and 28.4 minutes respectively versus 10.3 minutes for placebo at month 1 (P<0.001 for both) [8].

These numbers are not statistically different from each other. No head-to-head RCT between suvorexant and lemborexant has been published as of early 2025, so direct efficacy comparisons are cross-trial inferences at best. The Cochrane Collaboration's 2022 network meta-analysis of sedative-hypnotics included both drugs and placed lemborexant 10 mg among the highest-ranked agents for sleep maintenance outcomes (SUCRA 0.79) while suvorexant 20 mg ranked somewhat lower (SUCRA 0.63) for the same outcome, though the confidence intervals overlapped substantially [9].

The AASM's 2017 clinical practice guideline on chronic insomnia states: "We suggest that clinicians use suvorexant as a treatment for sleep maintenance insomnia (versus no treatment) in adults" [10]. Lemborexant was not yet approved at the time of that guideline. An updated AASM statement has not yet restated the relative ranking of the two DORAs as of this publication.